Hepatocellular carcinoma, the predominant form of primary liver cancer, remains a formidable clinical challenge, particularly in its advanced stages where prognosis is grim. Traditional systemic therapies often provide only modest improvements, and the need for refined therapeutic strategies has been increasingly pressing. It is within this context that SBRT, a technology enabling highly precise and concentrated radiation delivery, has garnered interest alongside the rising success of molecularly targeted drugs and immunomodulatory treatments.

The meta-analysis synthesizes findings from nine distinct studies encompassing a patient cohort exceeding 20,800 individuals. Detailed analyses explored both efficacy endpoints—including overall survival (OS) and progression-free survival (PFS)—and safety outcomes, focusing on adverse events (AEs) of varying severity. These data sets provide robust statistical power facilitating a nuanced understanding of how combining SBRT with pharmacological interventions alters patient trajectories.

Notably, the combination strategy demonstrated a remarkable 55% improvement in one-year overall survival rates when compared with targeted agents or immunotherapies alone. This enhancement extended to two-year survival as well, where patients experienced a 63% greater chance of prolonged survival. These findings suggest that localized control of tumor burden via SBRT synergizes with systemic agents, mounting a dual-front attack on the malignancy.

Beyond overall survival, objective response rates also improved substantially. The pooled risk ratio of 1.87 indicates nearly double the likelihood of tumor shrinkage or stabilization in patients receiving the combined regimen. This enhanced tumor response inherently translates into tangible clinical benefits, potentially delaying disease progression and improving patients’ quality of life.

The mortality risk analysis, quantified by hazard ratios, further underscored the protective effect of the combined approach. Patients treated with SBRT alongside pharmacotherapy saw their risk of death reduced by approximately 46%, while their likelihood of disease progression dropped by 51%. Such statistics underscore a profound impact on the natural course of advanced HCC.

Importantly, the amplified efficacy did not come at the cost of increased toxicity. The incidence of overall adverse events remained stable, with risk ratios near unity, signifying no statistically meaningful escalation in side effects. Even severe toxicities, categorized as grade 3 or higher, did not show a significant uptick, supporting the safety of integrating SBRT into systemic treatment frameworks.

These findings herald a potential paradigm shift in managing advanced HCC. The precise ablative capacity of SBRT may mitigate tumor burden efficiently, while targeted agents and immune checkpoint inhibitors engage molecular pathways and immune mechanisms to curtail cancer growth and dissemination. Their convergence could represent an optimized treatment axis, balancing potency with tolerability.

Professional oncologists and radiation specialists might find these results particularly compelling, as they suggest incorporating SBRT could elevate the standard of care. Previously, radiation therapy in HCC was often constrained by concerns over hepatic toxicity and limited efficacy, but technological advancements underpinning SBRT have forged new ground.

The meta-analysis methodology entailed rigorous selection and integration of heterogeneous studies differing in design and patient demographics, lending credibility and generalizability to the conclusions. Both fixed and random-effects models were employed to account for inter-study variance, ensuring robust and replicable observations.

This research is timely considering the expanding arsenal of targeted agents and immune therapies approved for HCC treatment. The ability to safely combine these systemic options with localized radiation could empower clinicians to tailor treatment plans more precisely, adapting to patient characteristics and disease burden.

Furthermore, investigations into mechanisms underlying synergy between SBRT and pharmacological agents are warranted. Hypothesized biological interactions include enhanced antigen presentation and immune activation triggered by radiation-induced tumor cell death, potentially augmenting immunotherapy efficacy.

The trial registration and adherence to systematic review protocols bolster the transparency and reproducibility of this study. Researchers globally can build upon these insights, refining protocols and exploring optimal sequencing or combinations to further improve patient outcomes.

In summary, the emerging evidence positions SBRT plus targeted and immunotherapeutic agents as a promising, safe, and effective combinatorial approach for advanced HCC. This integrated strategy could redefine treatment paradigms, offering improved survival and tumor control without added toxicity burdens.

As cancer therapeutics increasingly embrace precision and multimodal tactics, these results exemplify the potential of harnessing complementary modalities. This meta-analysis inspires optimism that future innovations will continue to translate into meaningful clinical advantages for patients battling hepatocellular carcinoma.

Subject of Research: Hepatocellular carcinoma treatment efficacy and safety

Article Title: Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis

Article References:
Hou, S., Hu, S., Wu, Q. et al. Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis. BMC Cancer 25, 1602 (2025). https://doi.org/10.1186/s12885-025-15061-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15061-4

This multi-institutional trial enrolled 698 evaluable participants, randomly assigning them to either a regimen of SBRT at a dose of 36.25 Gy delivered in 5 fractions or to MH-IMRT administered either as 70 Gy in 28 fractions or 60 Gy in 20 fractions. The core objective was to evaluate patient-reported outcomes using the expanded Prostate Cancer Index Composite (EPIC-26) questionnaire, specifically focusing on the bowel and urinary irritation or obstruction domains at baseline, 12 months, and 24 months post-treatment. By assessing minimal clinically important decline (MCID), the study meticulously quantified nuanced changes in quality of life.

The EPIC-26 tool, a validated patient-reported outcome measure, enables quantification of symptoms impacting quality of life that are crucial for patients with prostate cancer, particularly in areas like bowel function and urinary control that often bear the brunt of radiation-induced toxicity. At the two-year mark post-treatment, the data demonstrated a statistically significant reduction in bowel-related MCID in patients treated with SBRT compared to those receiving MH-IMRT—34.9% versus 43.8% respectively, with a p-value of 0.034. This evidence implies a tangible benefit of SBRT in mitigating late bowel toxicity, a common and distressing side effect that compromises patients’ well-being.

Importantly, the trial also explored urinary health outcomes, analyzing the frequency of minimal clinically important declines related to urinary irritative or obstructive symptoms. Contrary to the bowel domain observations, urinary symptom rates did not differ significantly between SBRT and MH-IMRT groups, with respective MCID frequencies of 33.7% versus 34.7% (p=0.68). Despite this, secondary genitourinary metrics, including incontinence-related quality of life and erectile function maintenance, showed favorable trends with SBRT, highlighting its nuanced advantages in functional outcomes beyond primary endpoints.

Beyond quality-of-life measures, one of the pivotal co-primary endpoints was disease-free survival (DFS). The interim results of the study revealed that SBRT did not demonstrate superiority over hypofractionated IMRT in extending DFS at the three-year follow-up, with this co-primary endpoint crossing futility boundaries due to a higher rate of biochemical failure determined by prostate-specific antigen (PSA) levels in the SBRT arm. While this finding tempers expectations regarding SBRT’s oncologic superiority, it accentuates the necessity for prolonged follow-up to ascertain long-term efficacy beyond the current timeframe.

The trial’s findings dovetail with prior research, such as the PACE-B study, which established the non-inferiority of SBRT compared to conventional IMRT protocols. However, NRG-GU005 distinguishes itself by emphasizing patient-reported outcomes, underscoring the principle that therapeutic regimens must not only aim for tumor control but must also prioritize the preservation of patients’ quality of life during survivorship—a factor of immense importance in localized prostate cancer management where survival outcomes are generally favorable.

Notably, the improved bowel health outcomes observed with SBRT may be attributed to its precise, high-dose, hypofractionated delivery that minimizes radiation exposure to surrounding rectal tissues. Additionally, the use of rectal spacers during SBRT procedures further enhances tissue sparing, contributing to favorable quality-of-life metrics and affirming technical refinements’ role in optimizing radiation therapy’s therapeutic ratio.

The rigorous design of NRG-GU005 included serial administrations of EPIC-26 at critical intervals, securing high compliance rates—82.5% for MH-IMRT and 85.1% for SBRT at two years post-treatment. This robust data collection strengthens the confidence in these findings and provides a comprehensive picture of treatment-associated morbidity in a real-world clinical context. EPIC-26’s dual-domain evaluation of bowel and urinary health offers nuanced insights into subclinical and clinical symptom trajectories over time.

As Dr. Rodney J. Ellis from the University of South Florida, lead author of the NRG-GU005 abstract, noted, the trial’s findings substantiate SBRT as a compelling option that balances oncologic outcomes with patient-centered quality-of-life gains. While urinary irritation or obstruction did not significantly improve, the favorable secondary genitourinary endpoints suggest SBRT’s potential in mitigating other dimensions of treatment-related morbidity.

Equally crucial is the trial’s spotlight on the evolving paradigm of radiation fractionation in prostate cancer. Hypofractionated regimens like SBRT deliver a larger dose per fraction over fewer treatment sessions, offering logistical advantages such as reduced overall treatment time and improved resource utilization, which are increasingly relevant in busy oncology practices and for patient convenience.

Nonetheless, the absence of clear DFS superiority calls for cautious interpretation. While early biochemical recurrence may be higher, long-term oncologic outcomes remain the gold standard for treatment evaluation. Therefore, sustained longitudinal follow-up is imperative to fully characterize the risk-benefit balance and to ascertain whether the quality-of-life gains with SBRT can be maintained without compromising cancer control.

In light of these findings, clinical decision-making for localized intermediate-risk prostate cancer should integrate patient preferences, treatment logistics, potential side effect profiles, and long-term oncologic considerations. NRG-GU005 enriches the evidence base supporting SBRT as a viable and potentially preferred treatment option, especially for patients prioritizing bowel health and overall quality of life without sacrificing efficacy.

Funding for NRG-GU005 was robust, sourced from several National Cancer Institute grants, reflecting the collaborative effort between the NRG Oncology research network and federal agencies committed to advancing prostate cancer therapeutics. This level of investment underscores the critical importance placed on refining radiation modalities to optimize outcomes for patients worldwide.

The broader implications of this study resonate profoundly within clinical oncology, as the balance between treatment efficacy and quality of life becomes increasingly central to therapeutic strategies. NRG-GU005’s findings are expected to influence clinical guidelines, radiation oncology practices, and patient consultations, fostering a more nuanced, patient-centric approach to prostate cancer treatment in the modern era.

For those eager to delve deeper, a special episode of the NRG Oncology Podcast features an in-depth discussion with Dr. Rodney Ellis on the trial’s results and their clinical significance. Available across platforms such as Spotify, Apple Podcasts, and YouTube, this podcast serves as a valuable educational resource for clinicians, researchers, and patients alike.

In summary, the NRG-GU005 trial represents a landmark step forward in evaluating radiation strategies for intermediate-risk prostate cancer. By conclusively demonstrating that SBRT can improve bowel-related quality of life without compromising short-term disease control, this research propels SBRT into a favored position in the therapeutic armamentarium—heralding a future where precision radiation delivers not only cure but also compassionate, patient-centered care.

Subject of Research:
Localized intermediate-risk prostate cancer treatment outcomes comparing SBRT and hypofractionated IMRT.

Article Title:
Primary results from NRG-GU005: A Phase III Trial of SBRT vs. Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer.

News Publication Date:
September-October 2025.

Web References:

• NRG Oncology Podcast
• Spotify
• Apple Podcasts
• YouTube Podcast Channel
• NRG Oncology Official Website

References:
Ellis RJ, Pugh SL, Yu JB, Feng FY, Konski AA, Grubb III RL, Wallace RE, Gladstone DJ, Ménard C, Frazier AJ, Pennington JD, Michalski JM, Spratt DE, Martinez A, Morgan SC, Mihai A, Paulus R, Sander HM. Primary results from NRG-GU005: A Phase III Trial of SBRT vs. Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer. Paper presented during the Plenary Session at the American Society for Radiation Oncology Annual Meeting, San Francisco, CA, 2025.

Keywords:
Prostate cancer, stereotactic body radiation therapy, hypofractionated intensity-modulated radiation therapy, radiation therapy, quality of life, patient-reported outcomes, EPIC-26, bowel health, urinary symptoms, disease-free survival, clinical trial, NRG-GU005, radiation oncology.

SAN FRANCISCO, September 29, 2025 — For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial. Patients treated with stereotactic body radiation therapy (SBRT) reported fewer declines in bowel, urinary and sexual functioning but were more likely to experience a rise in prostate-specific antigen (PSA). Initial results of the NRG Oncology GU005 trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

“These findings provide important new evidence to help guide treatment decisions for patients with localized prostate cancer, a disease with typically high cure rates and long life expectancy,” said Rodney Ellis, MD, principal investigator of the trial and a professor of radiation oncology at the University of South Florida/Tampa General Hospital. “The results help clarify what patients can expect from shorter versus longer courses of radiation therapy and enable more personalized treatment decisions based on individual priorities.”

Prostate cancer is the most common solid tumor in male patients. Roughly 70,000 U.S. adults each year are diagnosed with intermediate-risk disease confined to the prostate, for which radiation therapy is a standard treatment option. Historically, patients received external beam radiation in 35 to 45 daily sessions over seven to nine weeks, but research over the past decade has established moderately hypofractionated courses of 20 to 28 sessions over four to six weeks as equally effective.

More recently, investigators have tested whether SBRT, which delivers higher doses in as few as five sessions, can further shorten the course of therapy while maintaining high cure rates. SBRT uses advanced imaging and treatment planning techniques to target tumors with extreme precision, minimizing radiation exposure to nearby organs such as the bladder and rectum. The approach offers practical advantages, including fewer visits, less travel and lower average costs, but it requires specialized technology and expertise that may not be widely available.

The NRG-GU005 trial was designed to test whether SBRT would outperform moderately hypofractionated radiation for both cancer control and patient-reported outcomes. Researchers enrolled 698 patients with previously untreated, intermediate-risk localized prostate cancer across multiple centers internationally from 2017 to 2022.

Participants were randomly assigned to receive either SBRT (36.25 Gy in five fractions, n=353) or moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT, 70 Gy in 28 fractions or 60 Gy in 20 fractions, n=345). Co-primary endpoints combined clinical measures of disease control with patient-reported outcomes collected via questionnaires administered at baseline, 12 months and 24 months after treatment to track whether patients experienced clinically meaningful declines in bowel, urinary or sexual functioning.

Fewer patients treated with SBRT reported a clinically meaningful decline in bowel function at two years (34.9% vs. 43.8% with MH-IMRT, p=0.034). Overall urinary quality of life was equivalent between the groups, but urinary incontinence was less common two years after SBRT (declines for 25.9% vs. 34.7% with MH-IMRT, p=0.023). Sexual function scores favored SBRT at one year (34% vs. 44%, respectively, p=0.026) but were similar at two years (43 vs. 41%, p=0.67).

Regarding disease-free survival, 88.6% of patients in the SBRT group were free from disease progression after three years, compared to 92.1% receiving longer courses of radiation. The difference was driven mainly by higher rates of biochemical failure, or rising PSA after treatment, in the SBRT arm (7.8% vs. 4.2%, p=0.037).

“The PSA findings require careful interpretation,” noted Dr. Ellis. “With treatments involving larger doses per fraction, patients can experience temporary PSA elevations, or ‘benign bounces,’ that resolve over time. We need five-year follow-up to determine whether these elevations translate into actual disease progression.”

The GU005 trial used a lower total SBRT dose than other recent studies (36.25 vs. 40 Gy), which Dr. Ellis said may alternatively explain the higher rate of PSA progression. By comparison, the PACE-B trial, reported at ASTRO in 2023, found equivalent cancer control with the higher dose, though with increased bowel side effects. Longer follow-up from GU005 will help clarify whether the lower dose affects long-term outcomes.

Local recurrence rates did not differ between the arms (1.2% SBRT vs. 1.0% MH-IMRT at 3 years, p=0.97), and three-year overall survival was equally high at 97% in each group (p=0.62). Severe genitourinary complications were rare with either treatment, though less common with SBRT (0.6% vs. 2.5%, p=0.04).

The study also found that rectal spacers, which are gel-like devices that temporarily separate the rectum from the radiation field, appeared to reduce bowel side effects in both treatment groups when used (in 56% of patients on the SBRT arm and 55% on the IMRT arm).

Dr. Ellis said future research will address SBRT’s potential for patients with higher-risk disease and test additional strategies to further reduce side effects while maintaining survival outcomes. For now, he said patients with intermediate-risk prostate cancer have clearer information to guide their treatment decisions: more convenient treatment with better quality of life outcomes, or longer therapy courses with potentially stronger biochemical cancer control.

“Patients have different priorities and values when it comes to their care,” Dr. Ellis noted. “Some may prioritize convenience and minimizing impact on daily life, while others focus primarily on achieving the strongest possible cancer control measures. These results help inform those deeply personal decisions.”

###

This release includes updated study results/data from the authors. Attribution to the American Society for Radiation Oncology (ASTRO) Annual Meeting is requested.

Register here for a news briefing featuring this study on Tuesday, Sept. 30 at 8:00 a.m. Pacific.

Study and Presentation Details

• Abstract 1: Primary results from NRG-GU005: A phase III Trial of SBRT vs. hypofractionated IMRT for localized intermediate risk prostate cancer
• Session details and virtual meeting link
• Dr. Ellis’ bio and disclosures
• The NRG-GU005 trial (NCT03367702) was conducted by NRG Oncology with support from the National Cancer Institute and the National Institutes of Health
• More information about the meeting can be found in our press kit.

About ASTRO
The American Society for Radiation Oncology (ASTRO) is the world’s largest professional society dedicated to advancing radiation oncology, with 10,000 members including physicians, nurses, physicists, radiation therapists, dosimetrists and other professionals who work to improve patient outcomes through clinical care, research, education and policy advocacy. Radiation therapy is integral to 40% of cancer cures worldwide, and more than one million Americans receive radiation treatments for their cancer each year. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and media center and connect with us on social media.

Meeting

American Society for Radiation Oncology (ASTRO) 2025Annual Meeting

Non-small cell lung cancer is the most common form of lung malignancy, constituting approximately 85% of lung cancer cases worldwide. Historically, surgical intervention has been the gold standard for early-stage NSCLC, primarily due to its direct removal of localized tumors. However, surgery is invasive and can be contraindicated in patients with limited pulmonary reserve or comorbid conditions. SBRT has emerged as a non-invasive alternative, delivering ablative doses of radiation with sub-millimeter accuracy, minimizing damage to surrounding healthy lung tissue.

The study, led by Dr. Joe Chang, Ph.D., M.D., professor of Radiation Oncology, alongside Dr. Troy Kleber, a radiation oncology resident, represents one of the most robust datasets comparing these treatment modalities. Employing a cohort of patients with early-stage NSCLC, they tracked clinical outcomes over a 10-year period, meticulously analyzing overall survival, disease-free survival, and quality-of-life indices. The findings underscore that SBRT is not only a viable substitute for surgery but also offers distinct benefits in maintaining post-treatment functional status.

Delving into the technical dimensions, SBRT leverages advanced imaging techniques and motion management to deliver high doses of ionizing radiation across few fractions, often 1 to 5 sessions. The precise targeting capabilities stem from an integration of computed tomography (CT) simulation, four-dimensional imaging to track respiratory motion, and real-time image guidance technologies, all converging to confine radiation to tumor volumes while sparing adjacent critical structures. This precision reduces acute and chronic toxicities traditionally associated with broader-field radiotherapy.

Comparatively, surgical resection involves anatomical removal ranging from wedge resections to lobectomies, depending on tumor size and location. While surgery is definitive, it poses risks including postoperative complications, prolonged recovery times, and impacts on pulmonary function. The extended follow-up data from this study compellingly reveal that patients receiving SBRT experienced survival rates akin to those who underwent surgical intervention, challenging longstanding clinical dogmas.

Quality of life, a pivotal consideration in cancer care, also favored the radiation cohort according to the presented data. Patients treated with SBRT reported better preservation of respiratory function and fewer limitations in daily activities. Metrics assessing fatigue, pain, and physical function were systematically gathered via validated patient-reported outcome measures, highlighting the holistic benefits of radiation. This aspect provides a compelling narrative for clinicians and patients navigating treatment decisions balancing efficacy with life post-treatment.

The implications of this data transcend clinical practice, as the equivalence in survival with superior quality of life suggests a paradigm shift where SBRT could be prioritized for medically inoperable patients or those hesitant about surgery. Moreover, these results propel further investigation into combining SBRT with emerging systemic therapies, such as immunotherapy, potentially enhancing tumor control while reducing systemic toxicities.

Mechanistically, SBRT induces tumoricidal effects through direct DNA damage and vascular disruption. The high-dose hypofractionated approach maximizes biological effectiveness, exceeding the damage thresholds achievable with conventional fractionation. This leads to enhanced tumor cell apoptosis and secondary immune activation, which may explain the durable local control observed. The study emphasizes integrating radiobiological understanding with clinical data to optimize treatment protocols.

The researchers also discussed advancements in radiation delivery platforms that have facilitated these outcomes. Innovations such as intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), and image-guided systems have refined dose conformity and treatment reproducibility. Incorporating respiratory gating and motion compensation further ensures consistent targeting, crucial for tumors in the lung where breathing-induced displacement presents significant challenges.

Notably, this research fills a critical gap, as prior studies have often been limited by shorter follow-up durations or smaller sample sizes, hindering definitive conclusions. The rigorous design, incorporating stringent patient selection criteria and comprehensive follow-up, bolsters the validity of the findings. It also advocates for multidisciplinary collaboration in lung cancer care, highlighting the complementary roles of radiation oncologists, thoracic surgeons, and pulmonologists.

Looking forward, Dr. Chang and Dr. Kleber indicated plans to expand the investigation into molecular and genetic biomarkers that predict response to SBRT versus surgery. Personalized medicine approaches could further refine patient selection, maximizing therapeutic benefit while minimizing harm. Additionally, health economics analyses examining cost-effectiveness will be integral as healthcare systems consider adopting SBRT more broadly.

The presentation at ASTRO 2025 has already generated significant enthusiasm within the oncology community, reverberating across professional networks and social media. By demonstrating that cutting-edge radiation therapy can rival surgery in long-term efficacy while enhancing patient well-being, the study is poised to redefine standards of care in early-stage lung cancer.

In essence, this research from MD Anderson represents a milestone affirming that stereotactic body radiation therapy stands as a formidable alternative to surgery for early-stage NSCLC. It exemplifies the convergence of technological innovation, clinical rigor, and patient-centered outcomes research, ultimately enriching therapeutic choices for one of the world’s most lethal cancers.

Subject of Research: Early-stage non-small cell lung cancer treatment outcomes comparing stereotactic body radiation therapy and surgical resection over a 10-year period.

Article Title: Long-term survival and quality-of-life comparison between stereotactic body radiation therapy and surgery in early-stage non-small cell lung cancer.

News Publication Date: September 29, 2025

Web References: Not provided

References: Not provided

Image Credits: The University of Texas MD Anderson Cancer Center

Keywords: Non-small cell lung cancer, stereotactic body radiation therapy, surgery, survival outcomes, radiation oncology, quality of life, early-stage lung cancer, ASTRO 2025, long-term follow-up, radiotherapy technology